Taysha Gene Therapies (TSHA) Net Cash Flow (2020 - 2026)
Taysha Gene Therapies (TSHA) posted Net Cash Flow of -$43.2 million for Q1 2026, down 291.22% sequentially from $22.6 million in Q4 2025, and down 92.45% YoY from -$571.9 million in Q1 2025.
Taysha Gene Therapies (TSHA) Net Cash Flow (2020 - 2026) Analysis & Trends
Taysha Gene Therapies has reported Net Cash Flow for 7 years, with the latest figure at -$43.2 million in Q1 2026.
- Quarterly Net Cash Flow fell 92.45% year-over-year to -$43.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $160.1 million (up 2267.96% YoY) and the FY2025 annual result came in at $180.9 million, up 3788.72% from the prior year.
- Net Cash Flow fell to -$43.2 million in Q1 2026 per TSHA's latest filing, from $22.6 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $196.2 million in Q2 2025 and troughed at -$52.5 million in Q1 2022.
- A 5-year average of $7.5 million and a median of -$18.7 million in 2024 frame the typical range for Net Cash Flow.
- The widest YoY moves for Net Cash Flow: up 473.27% in 2023, down 138.03% in 2023.
- Over 5 years, Net Cash Flow stood at $53.6 million in 2022, then slumped by 138.03% to -$20.4 million in 2023, then climbed by 8.46% to -$18.7 million in 2024, then jumped by 221.1% to $22.6 million in 2025, then sank by 291.22% to -$43.2 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$43.2 million, $22.6 million, and -$15.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Taysha Gene Therapies | 1.94 Bn | 1.94 Bn | - | 176.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 176.23 Mn |
| Jun 30, 2026 | 176.23 Mn |
| Mar 31, 2026 | -43.19 Mn |
| Mar 31, 2026 | -43.19 Mn |
| Dec 31, 2025 | 22.59 Mn |
| Dec 31, 2025 | 22.59 Mn |
| Sep 30, 2025 | -15.42 Mn |
| Sep 30, 2025 | -15.42 Mn |
| Jun 30, 2025 | 196.17 Mn |
| Jun 30, 2025 | 196.17 Mn |
| Mar 31, 2025 | -22.44 Mn |
| Mar 31, 2025 | -22.44 Mn |
| Dec 31, 2024 | -18.65 Mn |
| Dec 31, 2024 | -18.65 Mn |
| Sep 30, 2024 | -15.06 Mn |
| Sep 30, 2024 | -15.06 Mn |
| Jun 30, 2024 | 48.76 Mn |
| Jun 30, 2024 | 48.76 Mn |
| Mar 31, 2024 | -19.96 Mn |
| Mar 31, 2024 | -19.96 Mn |